Spectra optia™ and elutra™ for the production of monocyte-derived dendritic cell vaccines

Technical Challenges in the Manufacture of Dendritic Cell Cancer Therapies

“…42 A 2014 study also showed that this system was able to isolate and enrich a highly purified MNC fraction (88.6% monocytes). 43 In a head-to-head study comparing Spectra Optia with other apheresis systems (COM.TEC and Amicus™ [Fresenius Kabi]), all devices resulted in similar total MNC yields. 44 The Spectra Optia device, however, collected significantly more CD14 + monocytes than the Amicus device (mean yield:…”